Question · asked by 1 review

Bae: AZT/3TC/NVP vs AZT/3TC/NVP: Maternal Grade 3/4 Severe Adverse Events

Population
HIV‐infected pregnant women
Intervention
Bae: AZT/3TC/NVP
Comparison
AZT/3TC/NVP
Outcome
Maternal Grade 3/4 Severe Adverse Events

It is very uncertain whether jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 vs AZT/3TC/NVP
Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women1
It is very uncertain whether jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (very low certainty).
Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane Headline outcomes only
RR 1.18 [0.47, 2.97]1 study · 146 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women
2010 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.